The law firm said CEO Luis C. Pena and CSO Jeegar Patel sold shares on June 22 under Rule 10b5-1 plans, days before Evommune disclosed a Phase 2b failure for EVO756.
27d ago
verifying reliability
No specialized terms available for this topic.